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ABSTRACT 
Background: Despite the availability of inexpensive and effective tetanus-toxoid-containing vaccines, elimination of maternal and 
neonatal tetanus worldwide has become a herculean task, particularly in low-income countries due to poor immunization coverage. 
This study aimed to assess the perception and utilization of tetanus toxoid immunization among pregnant women attending a 
tertiary centre in North-West Nigeria. 
Materials and Methods: A cross-sectional study was conducted among 254 pregnant women (selected by systematic sampling 
technique) attending the antenatal clinic of Specialist Hospital, Sokoto, Nigeria. A structured interviewer-administered 
questionnaire was used to collect data on the research variables. Data were analyzed using IBM SPSS version 20 statistical computer 
software package. 
Results: Most, 221 (87.0%) of the 254 respondents had heard of tetanus toxoid (TT) immunization. Of these, only about half 
(51.1%) believed that it protects both mother and newborn baby from tetanus. Majority of respondents considered TT 
immunization to be effective in protecting against tetanus infection (73.3%) and also safe for both mother and baby (79.2%). About 
two-thirds of respondents (68.8%) had the misconception that a single dose of TT immunization protects from tetanus infection. 
Less than a quarter of respondents (23.6%) had received two or more doses of the vaccine. The main barriers to utilization of TT 
immunization were lack of awareness of the vaccine (41.8%), not being aware of its benefits (36.7%), and fear of side effects 
(21.5%) 
Conclusion: Despite high levels of perception of the effectiveness and safety of TT immunization, the respondents in this study had 
low levels of perception and utilization of the protective doses of the vaccine. Government and healthcare workers should scale-up 
education of the populace on TT immunization schedule and implement community based vaccination of women of child bearing 
age in North-West Nigeria. 
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INTRODUCTION 
Despite the availability of inexpensive and effective 
tetanus-toxoid-containing vaccines (TTCV), elimination of 
maternal and neonatal tetanus (MNT) worldwide has 
become a herculean task, particularly in low-income 
countries due to low immunization coverage, and recent 
data showed that MNT is still a public health problem in 14 
of the 59 countries at risk worldwide since year 2000.1  
While the 34,000 newborns deaths from neonatal tetanus 
in 2015 is still a high figure, it actually represents a 94% 
reduction since 1988, and the reduction is believed to be 
largely due to scaled-up immunization with TTCV following 
the launching of the global Neonatal Tetanus Elimination 
and subsequently the Maternal and Neonatal Tetanus 
Elimination (MNTE) initiative in 1989 and 1999 
respectively.2 Since tetanus cannot be eradicated because 
the spores are present in the environment worldwide, the 
MNTE initiative aims to reduce MNT cases to such low 
levels that the disease is no longer a major public health 
problem (defined as less than one case of neonatal tetanus 
per 1000 live births in every district) in all countries. This 
is to be achieved through provision of at least 2 doses of 
tetanus toxoid (TT2) to all pregnant women in high risk 
areas and 3 doses (TT3) to all women of child bearing age, 
promotion of clean delivery services to all pregnant women 
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(including clean cord care practices) and ensuring effective 
surveillance for maternal and neonatal tetanus.1 
Although, maternal and neonatal tetanus can be easily 
prevented by hygienic delivery and cord care practices, 
deliveries take place in unhygienic circumstances (as a 
result of the prevalent inequity in access to maternal, 
newborn and child health services) in many low- and 
middle- income countries (particularly in Asia and sub-
Saharan Africa where the 14 countries in which MNT is still 
a public health problem are located), putting mothers and 
their newborn babies at risk of a variety of life-threatening 
infection. Also, whereas immunization of pregnant women 
and women of child bearing age with TTCV has been found 
to be very effective in preventing MNT, its utilization 
remains low in these countries.1,3 In Nigeria, similar to the 
situation in other sub-Saharan African countries where 
MNT is still a public health problem, data from the National 
Demographic and Health Survey (NDHS) 2013 showed 
wide variation but generally poor utilization of health 
facility delivery services across the country, ranging from 
11.5% in the North-West geopolitical zone to 78% in the 
South-East; and with only 38% of deliveries across the 
country assisted by a skilled provider.4 The enormity of the 
danger posed by the poor obstetric care services across the 
continent is demonstrated by the finding in a study 
conducted at the Kilifi County Hospital, Kenya, that 
reported that 98% of the neonatal tetanus admissions at 
the hospital from 1999 to 2013 were home deliveries.5  
While evidence from studies has shown that immunization 
of pregnant women or women of child bearing age with 
two or more doses of tetanus vaccine (TT2+) protects the 
mother and the newborn baby from tetanus (with 94% 
reduction in mortality from neonatal tetanus), and at least 
80% TT2+ coverage is needed to achieve MNT 
elimination,6,7 data from the Nigeria Demographic and 
Health Survey (NDHS) 2013 showed wide variation and 
predominantly low TT2+ coverage rates across the 
country, ranging from 27.1% in the North-West 
geopolitical zone of the country (the study area) to 82.0% 
in the South-East zone; and with a national TT2+ coverage 
rate of 48%.4 
Similar to the situation in Nigeria, studies conducted in 
other sub-Saharan African countries including Ethiopia,8 
Kenya,9 and Benin Republic,10 also established a direct 
association between health facility utilization by pregnant 
women (particularly antenatal clinic attendance) and 
acceptance of TTCV by them, as the ANC visits avail the 
healthcare providers the opportunity to educate them on 
the benefits of TT immunization and its schedule. While the 
concomitantly low utilization of health facility delivery 
services and low TT2+ coverage rate in North-West Nigeria 
is not surprising, it is alarming as it exposes the 
vulnerability of women and newborns in the zone to 
tetanus infection and the dire consequences. 
In addition to utilization of health facility delivery services 
(particularly the number of antenatal clinic visits), 
maternal socio-demographic characteristics, awareness of 
vaccine, knowledge of the schedule, access issues, 
conflicting advice, perception on vaccine efficacy, safety 
concerns and attitude of healthcare providers have been 
identified as determinants of acceptance of TTCV in studies 
conducted in sub-Saharan Africa and other places.11-16  
It is therefore evident that assessment of perception and 
utilization of tetanus toxoid immunization by pregnant 
women is crucial to identifying the barriers to the 
acceptance of the vaccine, and in developing strategies for 
facilitating its acceptance by them. Little is known about 
the perception of tetanus toxoid immunization among 
pregnant women in Sokoto, Nigeria. This study was 
conducted to assess the perception and utilization of 
tetanus toxoid immunization among pregnant women 
attending a tertiary centre in North-West Nigeria. 
MATERIALS AND METHODS 
Study Design and Population 
A cross-sectional study was conducted among pregnant 
women attending the antenatal clinic of Specialist Hospital, 
Sokoto, Nigeria in April and May 2015. The hospital is a 
tertiary healthcare facility located in Sokoto metropolis 
with a bed capacity of 270. It caters for the inhabitants of 
Sokoto metropolis and those referred from the health 
facilities in the Local Government Areas in Sokoto State, 
Nigeria. The Obstetrics and Gynaecology Department of the 
hospital runs the antenatal clinic thrice a week, seeing an 
average of 200 patients per day. Fresh attendees 
presenting for booking are seen on Wednesdays, while 
those presenting for revisits are seen on Tuesdays and 
Thursdays. Only those presenting for revisits were 
considered eligible and enrolled into this study. 
The sample size was estimated at 245 using the Fisher’s 
formula for calculating sample size for cross-sectional 
studies,17 a 20.0% prevalence of women of child bearing 
age that had received two or more doses of tetanus toxoid 
vaccine in a previous study,18 and a precision level of 5%. 
This was adjusted upwards to 260 based on an anticipated 
participant response rate of 95%. The eligible participants 
were selected by systematic sampling technique; 1 of 7 
pregnant women presenting consecutively for revisits at 
the antenatal clinic of the hospital was recruited over a 6-
week period until the required sample size was obtained. 
Data Collection and Analysis 
A standardized, structured, interviewer-administered 
questionnaire was developed and used to obtain 
information on the participants’ socio-demographic 
characteristics, and their perception and utilization of 
tetanus toxoid immunization. It was reviewed by 
researchers in the Department of Community Health, 
Usmanu Danfodiyo University, Sokoto, Nigeria. Corrections 
were made based on their inputs on content validity. The 
questionnaire was pretested on 20 pregnant women 
attending the antenatal clinic of Maryam Abacha Women 
and Children Hospital, Sokoto, Nigeria; the questions were 
well understood and no modification was necessary. Five 
resident doctors assisted in questionnaire administration 
after being trained on the conduct of survey research, the 
objectives of the study, and questionnaire administration.  
Data were analyzed using IBM Statistical Package for the 
Social Sciences (SPSS) version 20 statistical computer 
software package. Quantitative variables were summarized 
using mean and standard deviation, while categorical 
variables were summarized using frequencies and 
percentages; and the results were presented as frequency 
distribution tables. 
Ethical Consideration 
Institutional ethical clearance was obtained from the 
Ethical Committee of Sokoto State Ministry of Health, 
Sokoto, Nigeria. Permission to conduct the study was 
obtained from the management of the hospital, and 
informed written consent was also obtained from the study 
participants before questionnaire administration. 
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RESULTS 
Socio-demographic characteristics of respondents 
Two hundred and fifty-four of the 260 questionnaires 
administered were completely filled and retrieved, giving a 
response rate of 97.7%. The ages of the respondents 
ranged from 15 to 48 years (mean = 28.76 ± 4.31), but 
majority of them 137 (53.9%) were aged 20 – 29 years. 
Almost all, 246 (96.9%) of the 254 respondents were 
married, and most of them (206, 81.1%) were Muslims. 
Majority of the respondents were of Hausa/Fulani ethnic 
group (170, 66.9%), had secondary and tertiary education 
(176, 69.3%), were housewives (132, 52.0%) and had ≤ 4 
children (188, 74.0%) as shown in Table 1. 
 
Table 1: Socio-demographic characteristics of 
respondents 
 
 
 
Awareness of tetanus toxoid immunization by 
respondents 
Most, 221 (87.0%) of the 254 respondents had heard of 
tetanus toxoid immunization. Of these, majority 137 
(62.0%) obtained information on TT immunization from 
healthcare workers (during antenatal clinic sessions). 
Other common sources of information on TT immunization 
among the respondents were friends/relatives (20.8%) 
and the mass media (12.2%) as shown in Table 2.  
 
Table 2: Awareness of tetanus toxoid immunization by 
respondents 
 
 
Respondents’ perception of tetanus toxoid 
immunization 
Only about half, 113 (51.1%) of the 221 respondents that 
were aware of tetanus toxoid (TT) immunization believed 
that it protects both mother and newborn baby from 
tetanus. Majority of respondents (150, 67.9%) had the 
misconception that TT immunization is recommended for 
pregnant women only. While majority of respondents 
considered TT immunization to be effective in protecting 
against tetanus infection (73.3%) and also safe for both 
mother and baby (79.2%), about a tenth of respondents 
(10.9%) had the misconception that it is harmful to the 
baby. About two-thirds of respondents (68.8%) had the 
misconception that a single dose of TT immunization 
protects from tetanus for some years, while about half of 
them (50.7%) had the misconception that two or more 
doses protect from tetanus for life (Table 3). 
Utilization of tetanus toxoid immunization by 
respondents 
Majority, 175 (68.1%) of the 254 respondents had received 
at least 1 dose of tetanus toxoid (TT) immunization during 
pregnancy. Of these, only about a third 60 (34.3%) had 
received two or more doses of the vaccine. This implies 
that less than a quarter 60 (23.6%) of the 254 respondents 
had received two or more doses of the vaccine. Of the 79 
respondents that had never received the vaccine, the main 
reasons cited were lack of awareness of the vaccine 
(41.8%), not being aware of its benefits (36.7%), and fear 
of harm to self and/or baby (21.5%) as shown in Table 4.
 
 
 
 
 
Variables Frequency (%) 
 n = 254 
Age group (years) 
<20 
20-29 
30-39 
≥40 
 
 
23 (9.1) 
137 (53.9) 
81 (31.9) 
13 (5.1) 
Marital status 
Married 
Separated 
 
 
246 (96.9) 
8 (3.1) 
Ethnic group 
Hausa/Fulani 
Igbo 
Yoruba 
Others 
 
 
170 (66.9) 
23 (9.1) 
33 (13.0) 
28 (11.0) 
Religion 
Islam 
Christianity 
 
 
206 (81.1) 
48 (18.9) 
 
Level of education 
No formal education 
Primary 
Secondary  
Tertiary 
 
 
58 (22.8) 
20 (7.9) 
107 (42.1) 
69 (27.2) 
Occupation 
Housewife 
Trader / business woman 
Civil servant / professional 
 
 
132 (52.0) 
67 (26.4) 
55 (21.7) 
Number of children alive 
0-4 
5-9 
 
188 (74.0) 
66 (26.0) 
Variables 
 
Frequency 
(%) 
Ever heard of TT immunization         
(n = 254) 
Yes 
No 
 
 
 
221 (87.0) 
33 (13.0) 
Main source of information                
(n = 221) 
Mass media 
Health workers  
Friends/relatives 
Others (church, mosque) 
 
 
27 (12.2) 
137 (62.0) 
46 (20.8) 
11 (5.0) 
Awosan et al                                                                                                      Journal of Drug Delivery & Therapeutics. 2018; 8(6):119-124 
ISSN: 2250-1177                                                                                 [122]                                                                                  CODEN (USA): JDDTAO 
Table 3: Respondents’ perception of tetanus toxoid (TT) immunization 
Perception of TT immunization 
 
Frequency (%) 
(n = 221) 
Benefits of TT immunization 
Protects only the mother from tetanus 
Protects only the newborn baby from tetanus 
Protects both mother and newborn baby from tetanus 
Don’t know 
 
 
44 (19.9) 
57 (25.8) 
113 (51.1) 
7 (3.2) 
Group of women for which TT immunization is recommended 
Women of child bearing age only 
Pregnant women only 
Both pregnant women and women of child bearing age 
Don’t know 
 
 
27 (12.2) 
150 (67.9) 
35 (15.8) 
9 (4.1) 
Effectiveness of TT immunization in protecting from tetanus 
Effective 
Not effective 
Don’t know 
 
 
162 (73.3) 
6 (6.7) 
53 (24.0) 
Safety of TT immunization 
Harmful to the baby 
Harmful to the mother 
Safe for both mother and baby 
Don’t know 
 
 
24 (10.9) 
17 (7.7) 
175 (79.2) 
5 (2.3) 
Number of dose(s) of TT immunization that offer(s) protection from tetanus for some years 
One 
Two or more 
Five 
Don’t know 
 
 
152 (68.8) 
39 (17.6) 
26 (11.8) 
4 (1.8) 
 
Number of dose(s) of TT immunization that offer(s) protection from tetanus for life 
One 
Two or more 
Five 
Don’t know 
 
49 (22.2) 
112 (50.7) 
52 (23.5) 
8 (3.6) 
 
 
Table 4: Utilization of tetanus toxoid immunization during pregnancy by respondents 
 
 
 
DISCUSSION 
This study assessed the perception and utilization of 
tetanus toxoid immunization among pregnant women 
attending a tertiary centre in North-West Nigeria. While 
the high level of awareness of tetanus toxoid (TT) 
immunization among the respondents in this study 
(87.0%) is in consonance the with high levels of awareness 
of TT immunization in studies conducted in other cities in 
Nigeria including Lagos (89.0%),18 and Benin City (69%),19 
it is substantially higher than the low level of awareness 
(30.6%) reported in a recent study conducted in Duken 
Variables 
 
Frequency (%) 
Ever had TT immunization during pregnancy (n = 254) 
Yes 
No 
 
 
175 (68.9) 
79 (31.1) 
Total number of doses received during pregnancy (n = 175) 
One 
Two 
Three  
Four 
Five 
 
 
115 (65.7) 
33 (18.9) 
19 (10.9) 
6 (3.4) 
2 (1.1) 
 
Main reason for not receiving TT immunization during 
pregnancy (n = 79) 
Not aware of the vaccine 
Not aware of its benefits 
Fear of harm to self and/or baby 
 
 
33 (41.8) 
29 (36.7) 
17 (21.5) 
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Town, Eastern Ethiopia.8 This could be due to the efforts 
being made to eliminate MNT in Nigeria, being one of the 
countries where MNT is still a problem of public health 
importance in sub-Saharan Africa, unlike the situation in 
Ethiopia where the disease has been eliminated, and 
perhaps less attention is being given to it. It is therefore 
necessary to make the Government and other stakeholders 
in the countries where MNT has been eliminated know that 
promotion of TT immunization should be sustained to 
achieve at least 80% immunization coverage among 
pregnant women and women of child bearing age to be 
able to maintain the MNT elimination they have achieved in 
their respective countries (as recommended by the World 
Health Organization).1 
The finding of only about half (51.1%) of the respondents 
in this study believing that TT immunization protects both 
mother and newborn baby from tetanus, and most of them 
(67.9%) believing that it is recommended for only 
pregnant women suggests gaps in the sensitization of the 
populace about the disease, as most of them (62.0%) 
obtained information about the disease through health 
workers (during the antenatal clinic visit), who were 
probably mainly concerned with promoting the vaccine 
among their clients. Similar to the low level of sensitization 
of the populace on TT immunization through the mass 
media in this study (12.2%), only a tenth (10%) of 
respondents obtained information on TT immunization 
through the mass media in a study among pregnant women 
in Benin City,19 while another study among women in a 
Niger Delta community20 reported that none (0%) of the 
respondents obtained information about TT immunization 
through the mass media.  Contrary to the findings in 
studies conducted in Nigeria, reports from studies 
conducted in other sub-Saharan African countries not only 
showed higher utilization of the mass media in sensitizing 
the public about TT immunization, but also established an 
association between owning a radio or television and TT2+ 
uptake.8,10 These findings underscore the need for periodic 
and sustained sensitization of the populace about TT 
immunization through the mass media.   
The finding of most of the respondents in this study 
believing that TT immunization is effective in protecting 
from tetanus (73.3%) and safe for both mother and baby 
(79.2%) is reassuring, and it has serious implications on 
the acceptance of the vaccine by them considering the fact 
that doubts about the vaccine efficacy and safety concerns 
have been identified as barriers to uptake of TT 
immunization in studies conducted in many sub-Saharan 
African and Asia countries, particularly those where MNT 
has not been eliminated.10,21,22 
The finding of majority of the respondents in this study 
having the misconception that a single dose of the vaccine 
offers protection from tetanus for some years and that two 
or more doses offer protection from tetanus for life shows 
that they lack accurate information about the schedule for 
the vaccine. This is of serious concern as an erroneous 
perception of being protected by a single dose of the 
vaccine could make them not to complete the doses as 
specified in the immunization schedule, thus making them 
and their newborn babies vulnerable to tetanus infection. 
This is supported by the finding in a review by Wilson et 
al.12 that reported low knowledge about vaccines as one of 
the main barriers against tetanus vaccines acceptance in 
low-income countries. Similar to the finding in this study, 
studies conducted in other cities in Nigeria majorly 
reported poor awareness / knowledge of TT immunization 
schedule.18,20,21 A study among women of child bearing age 
in an urban district of Lagos, Nigeria,18 reported low 
awareness regarding the number of doses of vaccine 
required in pregnancy (14.4%) and for life protection 
(19.5%). Another study among women in a Niger Delta 
community of Nigeria reported that only 21.4% of 
respondents had good knowledge of TT immunization.20 A 
similar study among female undergraduate students in a 
Nigerian university21 reported that only 18.2% of 
respondents knew the complete dose of TT immunization.   
Although, majority of the respondents in this study 
(68.9%) have ever had TT immunization, less than a 
quarter of them (23.6%) had received two or more doses of 
the vaccine. This could be due to the poor awareness of TT 
immunization schedule by the respondents as majority of 
them (68.8%) erroneously believed that a single dose of 
the vaccine protects from tetanus, and the most common 
reasons cited by the respondents that never had TT 
immunization were lack of awareness of the vaccine 
(41.8%), and not being aware of its benefits (36.7%). These 
findings suggest the need for health workers to pay 
sufficient attention to educating pregnant women and 
women of child bearing age on TT immunization schedule 
(particularly its protective doses), its effectiveness in 
protecting mother and newborn baby from tetanus, and its 
safety in order to facilitate uptake of protective doses of the 
vaccine by them. 
While the 23.6% TT2+ uptake among the respondents in 
this study is almost twice the 12.6% TT2+ coverage among 
women of child bearing age in Sokoto State, Nigeria, it is in 
agreement with the 27.1% TT2+ coverage among women 
of child bearing age in North-West Nigeria (the study 
area).4 This could be due to the fact that the study was 
conducted in a tertiary health facility in an urban 
community. This is corroborated by the findings from the 
Nigeria Demographic and Health Survey (NDHS) 2013 
which showed that, while the national prevalence of 
women that received two or more doses of TT 
immunization in their last pregnancy was 48%, women in 
urban areas were almost twice as likely (70%) to have 
received two or more doses of TT immunization as 
compared to women in rural areas (36%).4 The low uptake 
of TT2+ among the respondents in this study, similar to the 
situation in the zone (North-West Nigeria), and with the 
zone having the lowest TT2+ coverage among women of 
child bearing age in Nigeria underscore the need for 
Government and healthcare workers to scale-up education 
of the populace on TT immunization schedule (particularly 
through the mass media) and implement community based 
vaccination of women of child bearing age in the zone. 
CONCLUSION 
Despite high levels of perception of the effectiveness and 
safety of TT immunization, the respondents in this study 
had low levels of perception and utilization of the 
protective doses of the vaccine. Government and 
healthcare workers should scale-up education of the 
populace on TT immunization schedule and implement 
community based vaccination of women of child bearing 
age in North-West Nigeria. 
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